Ana Griciuc

Dr. Ana Griciuc is a highly skilled neuroscientist specializing in Neuroinflammation, Innate Immunity, Disease Modeling, Drug Discovery, and Gene Therapy, particularly focused on neurogenerative diseases like Amyotrophic Lateral Sclerosis and Alzheimer's Disease.

Throughout her career, Dr. Griciuc has made significant contributions to understanding the roles of CD33 and TREM2 in microglia-mediated neuroinflammation and Alzheimer's disease pathogenesis.

Her research involves preclinical drug discovery and gene therapy studies targeting neuroinflammation mechanisms in Alzheimer's disease.

Dr. Griciuc excels in various techniques such as high-throughput drug screening, cell culture, FACS sorting, confocal microscopy, genomics, CRISPR/Cas9 gene editing, and bioinformatic analysis, among others.

She holds a Ph.D. in Neuroscience with Summa cum laude honors from the Helmholtz Research Center Munich and a Master's degree in Biochemistry from Université Claude Bernard Lyon 1.

Moreover, she pursued an engineering degree in Biochemistry and Biotechnology with a Master of Engineering from Institut national des Sciences appliquées de Lyon and participated in an Erasmus academic exchange program in Biochemistry and Genetics at Karlsruhe Institute of Technology.

Currently, Dr. Griciuc serves as an Assistant Professor of Neurology at Harvard Medical School and Massachusetts General Hospital, building on her prior roles as an Assistant in Neuroscience and an Instructor in Neurology at the same institutions.

Her earlier experience includes impactful roles as a Postdoctoral Research Fellow at Massachusetts General Hospital and HelmholtzZentrum München, as well as an involvement in the Marie Curie Actions program.

Dr. Griciuc's educational and professional journey also includes research stints at Max Planck Institute of Neurobiology and INSERM (Institut National de la Sante et de la Recherche Medicale), showcasing her versatile expertise and commitment to neuroscience.